Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HIV-1 Pol is a multifunctional polyprotein essential for the replication and maturation of the Human Immunodeficiency Virus type 1 (UniProt P03366). It is synthesized as a Gag-Pol precursor (p160) through a ribosomal frameshift and is subsequently cleaved by the viral protease into three distinct enzymes: protease (PR), reverse transcriptase (RT), and integrase (IN). The protease is responsible for processing viral polyproteins into functional units, reverse transcriptase converts the viral RNA genome into double-stranded DNA, and integrase facilitates the insertion of this DNA into the host cell genome (NIH: HIV Life Cycle). As a central component of the viral life cycle, Pol is the primary target for most antiretroviral therapies (ART), including protease inhibitors, reverse transcriptase inhibitors, and integrase inhibitors (FDA: Antiretroviral Drugs). In the context of HIV-MAG DNA, the Pol sequence is utilized as a vaccine antigen, often modified to eliminate enzymatic activity while retaining immunogenicity to elicit T-cell responses against conserved viral epitopes (: NCT00069511). This multi-antigen approach aims to provide broad protection by targeting multiple stages of the viral life cycle and reducing the likelihood of immune escape.
Inhibition of viral enzymes (protease, reverse transcriptase, or integrase) to prevent viral replication, genome integration, and maturation.
10 more in the full profile.
Source types: Peer-reviewed publication · Trial registry. Sources are available to Gosset users. Log in to see them.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HIV-1 Pol polyprotein (HIV-1 Pol).